معرفی
Thos Cochrane, MD, MBA is a medical ethicist, neuromuscular neurologist, and rare disease drug development specialist currently serving as Director of the Online Fellowship Certificate Program and Co-Director of the Fellowship in Bioethics at Harvard Medical School Center for Bioethics, alongside his role as Part-time Lecturer on Neurology at Harvard Medical School. Previously, he held positions as Assistant Professor of Neurology at Harvard Medical School and attending specialist in neuromuscular medicine and medical ethics at Brigham and Women's Hospital from 2005 to 2017.
Education:
- MD/MBA with honors from Tufts Medical School
- Neurology residency at Massachusetts General and Brigham and Women's Hospitals
- Neuromuscular medicine fellowship at Brigham & Women's Hospital
- HMS Fellowship in Bioethics (2004-2005)
Dr. Cochrane's research integrates medical ethics with neuromuscular therapeutics development, specializing in amyotrophic lateral sclerosis (ALS) interventions. His work bridges clinical neurology, neuroethics, and pharmaceutical innovation—particularly in antisense oligonucleotide (ASO) therapies and expanded access programs for rare neurological disorders. Current focus includes directing Quralis Inc.'s Clinical Development program for QRL-201, an intrathecal ASO targeting ALS.
Scientific Awards:
- Edmond J. Safra Faculty Fellow in Ethics, Harvard University (2005-2006)
Dr. Cochrane has not disclosed formal advisees or grant-funded research projects in the provided materials, though his leadership in establishing Biogen's Expanded Access Program for Tofersen demonstrates significant program development expertise. At Brigham and Women's Hospital, he consulted on medical ethics while maintaining clinical responsibilities.
He pioneered Biogen's Expanded Access Program for Tofersen (SOD1-ALS), enabling preapproval access for 400+ patients across 25+ countries. Currently, he leads Quralis Inc.'s Clinical Development team for QRL-201, advancing intrathecal ASO therapy for ALS through late-stage trials.
